Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
May 06 2021 - 1:00AM
Sanofi establishes three-year collaboration with Stanford Medicine
to accelerate immunology research
Sanofi establishes
three-year collaboration with
Stanford Medicine to accelerate
immunology research
- Projects led by collaborating researchers from the two
organizations will focus on autoimmune diseases and inflammatory
conditions
PARIS and Palo Alto,
CA – May 6,
2021 – Sanofi has entered into a
three-year research collaboration with Stanford University School
of Medicine. Together, the two organizations and their scientists
will work to advance the understanding of immunology and
inflammation through open scientific exchange. Additionally, Sanofi
will provide funding and scientific inputs into projects of mutual
interest, crossing multiple therapeutic areas including autoimmune
diseases and inflammatory conditions.
“We look forward to working with some of the
most innovative scientists in the human immunology community.
Together we will explore groundbreaking concepts and obtain deeper
insights into underlying inflammatory disease mechanisms,” said
Frank Nestle, Global Head of Research and Chief Scientific Officer,
Sanofi. "Sanofi’s collaboration with Stanford University aims to
transform how autoimmune disorders and inflammatory conditions are
understood and treated. It will help accelerate our ambitious
immunoscience programs as we advance a rich pipeline of first- and
best-in-class medicines across key therapeutic areas to address
unmet patient needs.”
Sanofi and Stanford Medicine will create a Joint
Steering Committee to fund up to three programs a year. Sanofi will
host an annual research forum for researchers from both
organizations to further exchange ideas, share knowledge and
perspectives on relevant scientific matters, and discuss
collaborative research projects.
“Stanford Medicine is dedicated to advancing
knowledge and discovery with the goal of improving our ability to
predict, prevent and cure disease with the most precise
approaches,” said Lloyd Minor, MD, Dean of the Stanford School of
Medicine. “The opportunity for long-term collaboration with our
colleagues at Sanofi will allow us to explore together new
frontiers in autoimmune diseases and inflammatory conditions.”
The collaboration will begin with three
"deep-dive" research projects:
-
Exploring cytokine crosstalk in type 2 inflammation, specifically
examining the impact of Sanofi’s investigational molecules on
excessive type 2 inflammation.
-
Decoding molecular drivers of effector and suppressor T cells in
autoimmunity, to better understand the specific antigens that may
cause type 1 diabetes.
-
Defining the mechanisms of immune-related adverse events with
immune checkpoint inhibitor therapy – with a focus on pneumonitis
and inflammatory arthritis – to explore the role of genomics and
pathogenic cell identification.
EDITOR’S NOTE: This new initiative is the latest
chapter in Sanofi’s long history of collaboration that includes the
Sanofi Innovation Awards (iAwards), a multi-institutional academic
partnership program designed to accelerate and innovative,
early-stage, disease-relevant research towards the clinic. The
iAwards represent one of the largest academic–industry
collaborations run by a biopharma company, and have generated early
research that has led to important scientific advancements in the
field, including contributions to Sanofi’s own pipeline.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering
Life |
Sanofi Media Relations Contact
Sally Bain Tel: +1 781-264-1091Sally.Bain@sanofi.com
|
Sanofi Investor Relations Contacts
ParisEva Schaefer-JansenArnaud
Delepine Sanofi Investor Relations
Contacts North AmericaFelix LauscherFara BerkowitzSuzanne
Greco Sanofi IR main line:Tel: +33 (0)1 53 77
45
45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact |
|
|
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2020. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. |
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024